# LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

> **NCT05983250** · PHASE3 · RECRUITING · sponsor: **Tenax Therapeutics, Inc.** · enrollment: 230 (estimated)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** TNX-103
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05983250
- **Lead sponsor:** Tenax Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-10
- **Primary completion:** 2026-10
- **Final completion:** 2028-10
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05983250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05983250, "LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05983250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*